{"id":"W2754562397","doi":"10.1016/s2213-8587(17)30313-3","title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"National Institute for Health and Care Research; Amgen","keywords":"Medicine; Evolocumab; PCSK9; Internal medicine; Diabetes mellitus; Type 2 diabetes; Clinical endpoint; Myocardial infarction; Stroke (engine); Cardiology; Endocrinology; Clinical trial; Cholesterol; Lipoprotein","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004424944,0.001712946,0.004278219,0.0004931006,0.0003688125,0.001477133,0.001149855,0.001649294,0.003813579],"category_scores_gemma":[0.006432669,0.0007464368,0.006778911,0.0005161138,0.001568119,0.001528712,0.0008575778,0.003322782,0.0003868203],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008533233,"about_ca_system_score_gemma":0.0006006598,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007526822,"about_ca_topic_score_gemma":0.001375649,"domain_scores_codex":[0.9971722,0.001732595,0.0002153197,0.0003991603,0.0002223283,0.0002584973],"domain_scores_gemma":[0.99524,0.002513705,0.001078356,0.0005793769,0.0001740193,0.0004145069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9819307,0.0003650871,0.003611491,0.0006112402,0.006388593,0.00004831146,0.00003136888,0.0002855198,0.0006649662,0.0001153526,0.0001845221,0.005762824],"study_design_scores_gemma":[0.9165544,0.03544571,0.03219184,0.000173858,0.01273702,0.0001333064,0.0000745759,0.0007812395,0.0006066688,0.0004968861,0.0007267131,0.00007786933],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884659,0.008930069,0.0003398579,0.000247265,0.0002487604,0.000236914,0.0006770371,0.00002772706,0.0008265204],"genre_scores_gemma":[0.9955622,0.001776504,0.0003834143,0.0003051342,0.000291794,0.0002100598,0.0008408206,0.00001170172,0.0006184978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004424944,"threshold_uncertainty_score":0.02340162,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007369601405536356,"score_gpt":0.238387942603715,"score_spread":0.2310183411981787,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}